Pharmacogenetics of warfarin elimination and its clinical implications.
about
Drug interactions with warfarin: what clinicians need to knowPharmacogenetics and anaesthesia: the value of genetic profilingWarfarin pharmacogenetics: does more accurate dosing benefit patients?Crystal structure of human cytochrome P450 2C9 with bound warfarinPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicinePharmacogenomics and drug response in cardiovascular disordersA case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirementA case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarkerDistal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarinPredicting in vivo drug interactions from in vitro drug discovery data.Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.In vitro and in vivo assessment of CYP2C9-mediated herb-herb interaction of Euphorbiae Pekinensis Radix and Glycyrrhizae RadixA Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertilityWarfarin dosage response related pharmacogenetics in Chinese population.Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Genotype and risk of major bleeding during warfarin treatment.Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Warfarin toxicity and individual variability-clinical case.Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by AgeNovel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Interaction of warfarin with drugs, natural substances, and foods.Rheonix CARD(®) Technology: An Innovative and Fully Automated Molecular Diagnostic DeviceEnantioselective pharmacokinetics of ibuprofen and involved mechanisms.Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery.The pharmacogenetics of coumarin therapy.Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.Pharmacogenetics of chronic cardiovascular drugs: applications and implications.Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.Pharmacogenetics of warfarin: current status and future challenges.Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients
P2860
Q24681312-1E638C1B-F2A1-4EB0-BBAF-7B64E1F570C5Q26859221-15AA68A3-F9D3-46BA-B220-364AA78EF3C7Q27027304-82E28EF6-B37C-4665-906B-512A2415D27EQ27641685-8A1E4915-2879-4AEF-9472-45B04C386851Q27692687-1D3B2724-8D35-483E-A8B9-C06D77471CA5Q28171051-DCA39362-0126-46E2-8579-D7DF37F48242Q28217697-738D2FE6-B73B-4097-A053-7A373577449EQ28468645-E4D07396-BDCD-4DD3-935D-44B930915CBEQ28476502-9D2218F3-263C-4EDF-A993-455DFC18EFDEQ28536483-8AB0E7E6-D379-47FD-BFF4-AA2465035BB3Q31011412-F14DEB52-A13A-4AA9-B82F-69ADC1EB7A26Q31049674-4AF2F1A0-584C-4E92-9EEF-5319F8F855C6Q33447738-DEAD306B-3558-439F-B64D-09E0C2EF7885Q34077598-461FBDBE-4F98-461A-8FEE-15A2CF6388FAQ34273608-E61F1B82-22C7-45C2-A783-60919882B531Q34348637-588F5C2A-BE07-48C2-A706-4BFFFF9EA755Q34417386-989A472E-E0B6-45CD-8470-746F28A40CBFQ34649093-237DF8E9-1D85-49CE-9E40-590FCE367409Q34977531-77F6D04F-D6F1-4C52-8992-4E96F5B04D1EQ34994877-82EAC7C6-3990-4B1B-AE19-65B07280C023Q35006973-251C4A54-C7BC-4F99-9B8D-594A2E88B4DEQ35092508-E0E7FE67-FF40-4C88-B92E-B6A719D7EB7DQ35129048-20EE63CA-4D28-4987-82CF-58272F1EEFF8Q35155651-DBE1FB99-6ECD-49FA-902A-11B0E020C962Q35204081-5F89BD47-63B6-43EF-8EF1-1B7705B2E526Q35475000-3F53FEF7-64B5-4147-AFD5-642D01C5830FQ35612111-A9B09E1C-9734-4E9A-8F50-22633CB9A8AAQ35814384-EE494EA4-5D72-4452-A032-BA6D569F454BQ35876954-420FB328-AA1B-44E8-84B0-D7841A5CF821Q36007599-D1267499-0B92-4AAC-BA1D-6E76A645D482Q36059904-105A3980-3AA9-4F34-BBC3-58AAA44C9F6FQ36061826-B5D5242D-DFB2-4670-9324-6C06655E8038Q36118277-65F35743-5C93-4D92-AAF8-00CA89E2C08CQ36192806-F624DEDC-880E-4485-BB3A-9A97B46CF2DBQ36219235-BA6D43F7-8CB3-4581-B417-7EC9B2CD0E5DQ36497020-10190E69-CFAC-4779-8BDD-FE7E496CEAD7Q36543128-C7B7F397-4EFD-4D21-8A3B-AC25E378082FQ36545011-3B138D20-91F2-4F2A-B474-33241CE50C01Q36597343-D06A5EB5-FE47-4DC5-89C3-293A633BDC96Q36741112-96990B5B-F875-4EE4-9E26-E953A6B6B2CD
P2860
Pharmacogenetics of warfarin elimination and its clinical implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacogenetics of warfarin elimination and its clinical implications.
@ast
Pharmacogenetics of warfarin elimination and its clinical implications.
@en
Pharmacogenetics of warfarin elimination and its clinical implications.
@nl
type
label
Pharmacogenetics of warfarin elimination and its clinical implications.
@ast
Pharmacogenetics of warfarin elimination and its clinical implications.
@en
Pharmacogenetics of warfarin elimination and its clinical implications.
@nl
prefLabel
Pharmacogenetics of warfarin elimination and its clinical implications.
@ast
Pharmacogenetics of warfarin elimination and its clinical implications.
@en
Pharmacogenetics of warfarin elimination and its clinical implications.
@nl
P1476
Pharmacogenetics of warfarin elimination and its clinical implications.
@en
P2093
Takahashi H
P304
P356
10.2165/00003088-200140080-00003
P577
2001-01-01T00:00:00Z
P5875
P6179
1013004371